PL3042669T3 - Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy - Google Patents

Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy

Info

Publication number: PL3042669T3
Authority: PL; Poland
Prior art keywords: cancer; agent; effect enhancing; enhancing agent; cancer effect
Prior art date: 2013-09-06

Application number

PL14842538.2T

Other languages

English (en)

Inventor

Hiroyuki Okabe

Original Assignee

Taiho Pharmaceutical Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-06

Filing date

2014-09-05

Publication date

2023-06-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3042669(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-05 Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.

2023-06-26 Publication of PL3042669T3 publication Critical patent/PL3042669T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Endocrinology (AREA)

PL14842538.2T 2013-09-06 2014-09-05 Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy PL3042669T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2013184684		2013-09-06
PCT/JP2014/073436 WO2015034032A1 (ja)	2013-09-06	2014-09-05	抗腫瘍剤及び抗腫瘍効果増強剤

Publications (1)

Publication Number	Publication Date
PL3042669T3 true PL3042669T3 (pl)	2023-06-26

Family

ID=52628493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14842538.2T PL3042669T3 (pl)	2013-09-06	2014-09-05	Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy

Country Status (25)

Country	Link
US (1)	US9943537B2 (pl)
EP (2)	EP3042669B1 (pl)
JP (2)	JP6425653B2 (pl)
KR (1)	KR101993963B1 (pl)
AU (1)	AU2014316030C1 (pl)
CY (2)	CY1126037T1 (pl)
DK (1)	DK3042669T3 (pl)
ES (1)	ES2946472T3 (pl)
FI (2)	FI3042669T3 (pl)
FR (1)	FR24C1005I1 (pl)
HR (1)	HRP20230523T1 (pl)
HU (2)	HUE062034T2 (pl)
LT (2)	LT3042669T (pl)
LU (1)	LUC00328I2 (pl)
NO (1)	NO2024005I1 (pl)
PL (1)	PL3042669T3 (pl)
PT (1)	PT3042669T (pl)
RS (1)	RS64243B1 (pl)
RU (1)	RU2682161C2 (pl)
SI (1)	SI3042669T1 (pl)
SM (1)	SMT202300167T1 (pl)
TW (1)	TWI641385B (pl)
UA (1)	UA121538C2 (pl)
WO (1)	WO2015034032A1 (pl)
ZA (1)	ZA201602258B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20230523T1 (hr)	2013-09-06	2023-08-04	Taiho Pharmaceutical Co., Ltd.	Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
WO2017119484A1 (ja)	2016-01-08	2017-07-13	大鵬薬品工業株式会社	免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤
US20190160054A1 (en) *	2016-04-13	2019-05-30	Boehringer Ingelheim International Gmbh	Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3646887A4 (en) *	2017-06-30	2021-03-24	Korea Advanced Institute of Science and Technology	CONJUGATE OF VEGF GRAB PROTEIN AND MEDICINAL PRODUCTS AND USES THEREOF
KR20220154986A (ko)	2021-05-14	2022-11-22	윤상은	휴대용 마스크끈 절단기
AR127893A1 (es) *	2021-12-10	2024-03-06	Servier Lab	Terapia del cáncer dirigida a egfr
TW202339786A (zh)	2022-01-21	2023-10-16	日商中外製藥股份有限公司	癌症之治療或預防用醫藥
JP7565132B2 (ja)	2022-04-20	2024-10-10	中外製薬株式会社	がんの治療又は予防用医薬
WO2024177036A1 (ja) *	2023-02-20	2024-08-29	大鵬薬品工業株式会社	Ｆｔｄ・ｔｐｉ配合剤、ｐｄ－１経路アンタゴニスト、及びｖｅｇｆ経路アンタゴニストの併用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100424934B1 (ko)	1995-03-29	2004-07-27	다이호야쿠힌고교 가부시키가이샤	우라실유도체및이를함유하는항종양효과증강제및항종양제
US7312243B1 (en) *	2003-08-29	2007-12-25	Jay Pravda	Materials and methods for treatment of gastrointestinal disorders
US7799783B2 (en) *	2005-01-26	2010-09-21	Taiho Pharmaceutical Co., Ltd.	Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP5576591B2 (ja)	2005-01-26	2014-08-20	大鵬薬品工業株式会社	α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
JP6002835B2 (ja) *	2013-03-27	2016-10-05	大鵬薬品工業株式会社	低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
KR101847252B1 (ko)	2013-03-27	2018-04-09	다이호야쿠힌고교 가부시키가이샤	이리노테칸염산염 수화물을 함유하는 항종양제
HRP20230523T1 (hr)	2013-09-06	2023-08-04	Taiho Pharmaceutical Co., Ltd.	Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta

2014
- 2014-09-05 HR HRP20230523TT patent/HRP20230523T1/hr unknown
- 2014-09-05 KR KR1020167005952A patent/KR101993963B1/ko active Active
- 2014-09-05 ES ES14842538T patent/ES2946472T3/es active Active
- 2014-09-05 US US14/916,878 patent/US9943537B2/en active Active
- 2014-09-05 RS RS20230421A patent/RS64243B1/sr unknown
- 2014-09-05 FI FIEP14842538.2T patent/FI3042669T3/fi active
- 2014-09-05 JP JP2015535524A patent/JP6425653B2/ja active Active
- 2014-09-05 SI SI201432026T patent/SI3042669T1/sl unknown
- 2014-09-05 TW TW103130882A patent/TWI641385B/zh active
- 2014-09-05 AU AU2014316030A patent/AU2014316030C1/en active Active
- 2014-09-05 PT PT148425382T patent/PT3042669T/pt unknown
- 2014-09-05 SM SM20230167T patent/SMT202300167T1/it unknown
- 2014-09-05 HU HUE14842538A patent/HUE062034T2/hu unknown
- 2014-09-05 RU RU2016112421A patent/RU2682161C2/ru active
- 2014-09-05 EP EP14842538.2A patent/EP3042669B1/en active Active
- 2014-09-05 UA UAA201603578A patent/UA121538C2/uk unknown
- 2014-09-05 WO PCT/JP2014/073436 patent/WO2015034032A1/ja not_active Ceased
- 2014-09-05 DK DK14842538.2T patent/DK3042669T3/da active
- 2014-09-05 PL PL14842538.2T patent/PL3042669T3/pl unknown
- 2014-09-05 LT LTEPPCT/JP2014/073436T patent/LT3042669T/lt unknown
- 2014-09-05 EP EP23154967.6A patent/EP4201424A1/en active Pending
2016
- 2016-04-05 ZA ZA2016/02258A patent/ZA201602258B/en unknown
2018
- 2018-01-15 JP JP2018004516A patent/JP6557744B2/ja active Active
2023
- 2023-06-07 CY CY20231100271T patent/CY1126037T1/el unknown
2024
- 2024-01-24 LU LU00328C patent/LUC00328I2/fr unknown
- 2024-01-24 FR FR24C1005C patent/FR24C1005I1/fr active Active
- 2024-01-24 HU HUS2400001C patent/HUS2400001I1/hu unknown
- 2024-01-24 CY CY2024001C patent/CY2024001I2/el unknown
- 2024-01-25 FI FIC20240002C patent/FIC20240002I1/fi unknown
- 2024-01-25 NO NO2024005C patent/NO2024005I1/no unknown
- 2024-01-26 LT LTPA2024502C patent/LTPA2024502I1/lt unknown

Also Published As

Publication number	Publication date
ZA201602258B (en)	2017-09-27
US20160193241A1 (en)	2016-07-07
SMT202300167T1 (it)	2023-07-20
WO2015034032A1 (ja)	2015-03-12
RU2016112421A (ru)	2017-10-11
HRP20230523T1 (hr)	2023-08-04
CY1126037T1 (el)	2023-11-15
SI3042669T1 (sl)	2023-07-31
PT3042669T (pt)	2023-06-15
LTPA2024502I1 (pl)	2024-03-12
CY2024001I1 (el)	2024-09-20
CY2024001I2 (el)	2024-09-20
US9943537B2 (en)	2018-04-17
UA121538C2 (uk)	2020-06-25
AU2014316030A1 (en)	2016-04-28
RS64243B1 (sr)	2023-06-30
LT3042669T (lt)	2023-06-26
NO2024005I1 (no)	2024-01-25
EP3042669A1 (en)	2016-07-13
JPWO2015034032A1 (ja)	2017-03-02
RU2016112421A3 (pl)	2018-06-20
EP3042669B1 (en)	2023-03-08
JP6425653B2 (ja)	2018-11-21
KR20160050026A (ko)	2016-05-10
TW201536319A (zh)	2015-10-01
AU2014316030B2 (en)	2019-02-28
LUC00328I2 (pl)	2026-03-04
ES2946472T3 (es)	2023-07-19
TWI641385B (zh)	2018-11-21
FIC20240002I1 (fi)	2024-01-25
FI3042669T3 (fi)	2023-05-25
EP3042669A4 (en)	2017-04-12
DK3042669T3 (da)	2023-06-12
RU2682161C2 (ru)	2019-03-15
JP6557744B2 (ja)	2019-08-07
FR24C1005I1 (fr)	2024-04-19
AU2014316030C1 (en)	2024-08-15
HUE062034T2 (hu)	2023-09-28
EP4201424A1 (en)	2023-06-28
JP2018076369A (ja)	2018-05-17
HUS2400001I1 (hu)	2024-02-28
KR101993963B1 (ko)	2019-06-27

Publication	Publication Date	Title
IL269045A (en)	2019-10-31	Aptamers and uses thereof
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
BR302014001267S1 (pt)	2015-05-12	Configuração aplicada em liquidificador
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
EP2889350A4 (en)	2016-05-18	ADHESIVE COMPOSITION
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
DK3077467T3 (da)	2023-01-09	Sikkativsammensætning og anvendelse deraf
EP2970569A4 (en)	2016-07-27	PERSISTENT CARBENE AND COMPOSITIONS WITH IT
BR302013005965S1 (pt)	2015-02-18	Configuração aplicada em otomana
PL3030519T3 (pl)	2022-05-23	Trójpierścieniowe związki benzoksaborolu i ich zastosowania
DK3027750T3 (da)	2019-07-15	Biokatalytisk sammensætning
PL3042669T3 (pl)	2023-06-26	Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
IL240248A0 (en)	2015-09-24	Met-binding agents and uses thereof
DE112014002764A5 (de)	2016-03-03	Schuh und Schuhset
DK3071053T3 (da)	2019-10-21	Præbiotisk sammensætning
EP3041028A4 (en)	2016-08-24	LAMINATE AND APPLICATION THEREOF
EP3012307A4 (en)	2016-06-29	MIXED REFRIGERANT
BR302013005862S1 (pt)	2015-02-10	Configuração aplicada em coador
DK3068428T3 (da)	2022-10-17	Annexin-ii-variant-sammensætninger og fremgangsmåder
FR3007291B1 (fr)	2015-07-17	Composition cicatrisante et utlisation
HRP20181735T1 (hr)	2018-12-28	Liposom za topikalnu primjenu i njegova uporaba
EP2985312A4 (en)	2016-09-21	AGGREGATE AND COMPOSITION
BR302013001974S1 (pt)	2014-06-03	Configuração aplicada em pnemático
BR302013005268S1 (pt)	2015-01-20	Configuração aplicada em muleta axilar
BR302013004044S1 (pt)	2014-06-10	Configuração aplicada em macação